Kosan Biosciences

Kosan Biosciences, Inc. (stock symbol: KOSN), is a pharmaceutical company which deals with cancer therapeutics medications.

Cancer drug development[edit | edit source]

The company is currently working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.

Technology[edit | edit source]

Their technology platform is based on manipulation of the genetic instructions of microbes for making natural product polyketides.

Rearranging the modular units in natural polyketide synthases,
combining modules from different enzymes,
and incorporating novel synthetic chemical starter units

This enables them to produce a wide variety of novel polyketides that would be difficult to obtain via organic synthesis alone.

History[edit | edit source]

Founded in 1995, Kosan is headquartered in Hayward, California and currently has approximately 90 employees.

Funding[edit | edit source]

Kosan was funded in part as a venture capital start-up with funds from Sofinnova Ventures of California.

Acquisition[edit | edit source]

On June 26, 2008, Kosan Biosciences was acquired by Bristol-Myers Squibb

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.